Seattle Genetic, Clay Siegall, & The Future of Cancer Research

The fight against cancer has been an ongoing struggle throughout the years. There has been substantial amounts of medications introduced on the market, but none of them have made a huge difference when it comes to eradicating this deadly disease. Fortunately times have changed as well as innovation and the fight against cancer has never looked brighter. Seattle Genetics is at the forefront of this change by offering some of the most advanced breakthrough therapies. One of the biggest reasons for this drastic change comes from President and CEO Clay Siegall.

Dr. Clay Siegall is one of the founders of this Biotech giant known as Seattle Genetics. he has laid the foundation of success which stems from his progressive way of thinking. The company goes by rigorous research, drug development, and scientific innovation for cancer research. Dr. Siegall is well versed and experienced as he’s been in the business for multiple decades. Throughout the years he has worked for prominent organizations such as Bristol Myers Squibb, The National Institute of Health, and The National Cancer Institute. Having this much experience has acclimated him to the top of the field with an impressive resume. Check out these accomplishment below:

Ph.D in Genetics
Currently Holds 15 Patents
(BS) in Zoology
Author of more than 70 publications
And more

The company’s success comes from it’s high quality breakthrough therapies and the drug (ADCETRIS) is the crown jewel. ADCETRIS has racked up $226 Million in 2015 alone in the U.S. and Canada. Expectations are though to be greater within a year from now and could be anywhere between $250-$275 Million is sales. Forbes Magazine ranked the company in it’s top 100 for the fastest growing companies in the nation. With so many more advanced medications in the works, Seattle Genetics and Dr. Clay Siegall will continue to revolutionize cancer research while changing the status quo.